**Summary of Futura Medical PLCs Half-Year Report (H1 2025):**
Futura Medical PLC, a consumer healthcare company specializing in sexual health products, reported its results for the six months ended 30 June 2025. The company faces challenges despite expanding its market presence for its lead product, Eroxon, to 25 countries. Key highlights include
### **Operational Overview**
**Eroxon Launches** Eroxon is now available in 25 countries, but usage and marketing communication challenges persist.
**Eroxon Intense** On track for regulatory approvals in the EU and USA by year-end 2025. A Home User Study in 200 UK erectile dysfunction (ED) patients has been commissioned.
**WSD4000** A topical treatment for female sexual dysfunction completed a successful Home User study in January 2025. A pre-submission meeting with the FDA occurred before the Early Feasibility Study in Q1 2026.
### **Financial Overview**
**Revenue** £1.0 million (H1 2024: £7.0 million), reflecting slower-than-expected sales of Eroxon, leading to suppressed 2025 demand due to excess 2024 inventory.
**Revenue Breakdown** 50% from US royalties, 48% from EU/UK product sales, and the remainder from LATAM and the Middle East.
**Gross Profit** £0.73 million (H1 2024: £1.7 million), excluding a £0.49 million provision for potential inventory obsolescence.
**Loss After Tax** £6.59 million (H1 2024: Profit £1.0 million), including £3.6 million in exceptional items (impairment of plant and equipment, inventory write-down, and final asset payment).
**Adjusted Loss** £2.0 million (excluding exceptional items and non-cash share-based payments).
**Cash Position** £3.69 million as of 30 June 2025 (H1 2024: £3.9 million).
### **Post-Period End and Outlook**
**Strategic Review** The Board initiated a strategic review in August 2025 to address challenges.
**Revenue Forecast** FY 2025 revenue expected to be materially <mark style="background-color:yellow">below</mark> expectations, between £1.3 million and £1.4 million, due to slower sales and delayed US patent milestone payment.
**Cash Runway** Cash of £2.71 million at the end of August 2025 is expected to last until January 2026. A cost-cutting program has been initiated to extend the cash runway.
**Exploring Options** The company is considering commercial and financing opportunities to extend its cash runway and create shareholder value.
**Leadership Changes** Key leadership changes include the departure of the CEO, CFO, and Non-Executive Chair, with an interim CEO appointed.
### **CEOs Comments**
Interim CEO Alex Duggan emphasized the need for a clear strategy to maximize shareholder value, acknowledging slower-than-expected consumer uptake of Eroxon. He highlighted the potential of Eroxon Intense and WSD4000, with development plans continuing despite challenges.
### **Financial Statements Highlights**
**Profit/Loss** A significant loss of £6.59 million, driven by exceptional items and slower sales.
**Cash Flow** Net cash used in operating activities was £2.979 million, with cash and cash equivalents at £3.69 million.
**Going Concern** The company faces material uncertainty due to losses and cash flow challenges but continues on a going concern basis.
### **Conclusion**
Futura Medical faces significant financial and operational challenges, including slower sales, inventory issues, and leadership transitions. However, the company remains focused on its strategic review, cost-cutting measures, and the development of Eroxon Intense and WSD4000 to drive future growth and shareholder value.